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Background/introduction
Transcranial MRI-guided focused ultrasound is a rapidly
advancing field for delivering therapeutic and imaging
agents to the brain. It has the ability to facilitate the pas-
sage of therapeutics from the vasculature to the brain par-
enchyma, which is normally protected by the blood-brain
barrier (BBB). Its main advantages are that it is targeted,
noninvasive, and readily repeatable in nature. Studies have
shown that it can deliver liposomal doxorubicin (DOX), a
chemotherapy agent with promise for tumors in the cen-
tral nervous system, into the brain across BBB. However,
prior studies have suggested that this agent may be signifi-
cantly neurotoxic, even at small concentrations. Here, we
studied whether multiple sessions of DOX administered
after FUS-induced BBB disruption (FUS-BBBD) caused
adverse events in the normal brain. First, we used fluoro-
metry to measure the doxorubicin concentrations in the
brain after FUS-BBBD. Next, we performed three weekly
sessions with FUS-BBBD ± DOX administration.
Methods
FUS-BBBD was produced in one hemisphere in 18 male
Sprague-Dawley rats (250-350g); the other hemisphere
served as a control. Nine animals were assigned to one
of two groups: (1) three weekly treatments with FUS
and concurrent chemotherapy (FUS+DOX) (N=5),
(2) three weekly treatments with FUS only (N = 4).
Sonications (0.69 MHz; 0.55-0.81 MPa; 10 ms bursts;
1 Hz PRF; 60s duration) were performed over three
weeks in a grid pattern at 5, 9, and 12 targets, respec-
tively, following a schedule described previously in a
survival study in glioma-bearing rats (Aryal et al.,
Journal of Control Release, 2013). Each sonication was
combined with an i.v. injection of Definity (10μl/kg).
DOX (5.67 mg/kg) was administered in fractions before
each sonication. Contrast enhanced T1-weighted ima-
ging and T2*-weighted imaging were used to confirm
BBBD and detect hemorrhage in the targeted areas,
respectively. The animals’ health was monitored regu-
larly, and MRI was obtained to evaluate treatment effects.
Seven weeks after the last treatment, animals were sacri-
ficed, and the brains were sectioned and stained for his-
tological analysis. To confirm that we were delivering
DOX liposomes across the BBB, nine additional animals
were sacrificed four hours after sonication (0.55 MPa;
nine targets in a 3×3 grid) and DOX concentrations were
measured in both hemispheres (sonicated and non-
sonicated) using fluorometry.
Results and conclusions
We found that clinically-relevant concentrations of dox-
orubicin (4.8±0.5 μg/g) were delivered to the brain with
the sonications parameters, microbubble concentration
(Definity, 10 μl/kg), and the administered DOX dose
used. We also noted that the resulting concentration was
reduced by 38% when the agent was injected 10 minute
after the last sonication. In histology, focal planes were
unaffected in rats who received FUS-BBBD but not DOX.
The brain of one rat who received FUS-BBBD and DOX
appeared unaffected at focal plane. Three others had
small scars and one had a small infarct. Overall this work
demonstrates that ultrasound can deliver clinically-rele-
vant concentrations of DOX across the BBB, particularly
when administered before the FUS exposures. The results
indicate that while delivery of DOX to the rat brain can
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earlier work does not appear to occur with delivery via
FUS-BBB disruption.
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